Skip to main content
Quest Diagnostics

Automated Chromatography Review of Comprehensive 113 Drug LCMSMS Panel in Urine

ADLM 2025

Association for Diagnostics and Laboratory medicine

Chicago, IL, July 27-31 , 2025

Poster presentation: Automated Chromatography Review of Comprehensive 113 Drug LCMSMS Panel in Urine

Authors: Hunt TJ, Sill DJ, Smith MP, Bartock SH

Medical Specialty: Prescription drug monitoring, Toxicology, Laboratory medicine

Related content

Publication
Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM)
Conference Presentation
Mass Spectrometric Screening for Drugs in Urine in the Clinical Toxicology Laboratory
Conference Presentation
Xylazine Detection in Clinical Urine Specimens Ordered for Comprehensive Drug Screening
Audio Podcast
Drug Testing for Stimulants
Test FAQ
Drug Monitoring, Assess Panel, Comprehensive, Qualitative, Urine
Audio Podcast
Presumptive vs Definitive Drug Testing: What You Need to Know

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.